NCT04416854View on ClinicalTrials.gov

The Value of Palliative Primary Tumor Resection in Metastatic Colon Cancer

PHASE3RecruitingINTERVENTIONAL
Enrollment

627

Participants

Timeline

Start Date

April 1, 2020

Primary Completion Date

December 31, 2023

Study Completion Date

December 31, 2025

Conditions
Metastatic Colon CancerSurgery
Interventions
PROCEDURE

resection of primary tumor

resection of primary lesion with unresectablely metastatic colon cancer

DRUG

XELOX

Oxaliplatin 130mg/m2 ivgtt d1 and capecitabine 1000mg/m2,bid,po,d1-d14,every three weeks for a cycle

DRUG

mFOLFOX6

Oxaliplatin 85mg/m2, leucovorin 400mg/m2 ivgtt d1 and 5-FU 400 mg/m2 IV bolus d1，2400 mg/m2 CIV 46h, d1

Trial Locations (1)

200032

RECRUITING

Fudan University Shanghai Cancer Center, Shanghai

All Listed Sponsors
lead

Fudan University

OTHER

NCT04416854 - The Value of Palliative Primary Tumor Resection in Metastatic Colon Cancer | Biotech Hunter | Biotech Hunter